

Media Release

10 October 2012

PRESENTATION OF DATA AT THE NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce that Bronchitol® is the subject of three presentations at the 26th annual North American Cystic Fibrosis Conference to be held in Orlando, Florida from October 10th – 13th. These presentations focus on new analyses of patient subgroups in the Phase 3 clinical trials.

The abstracts are available on the NACF conference website at: nacfconference.org

Abstract Number 192: *'Predicting sustained response to inhaled dry powder mannitol (Bronchitol) in patients with cystic fibrosis'*

Identification of predictors of response to long term therapy is important given that cystic fibrosis treatments are life-long. In this retrospective analysis of patients completing the previously reported Phase 3 trials, an improvement in lung function at 6 weeks was significantly correlated with a sustained response of the same magnitude over 26 weeks ($p < 0.0001$) in patients receiving Bronchitol.

Abstract Number 258: *'Improvements in lung function in Pseudomonas colonised patients treated with inhaled dry powder mannitol (Bronchitol).'*

Around 60% of patients with cystic fibrosis have chronic respiratory infection caused by *Pseudomonas aeruginosa*. In this subgroup analysis of *Pseudomonas* positive patients from the previously reported Phase 3 trials, the difference in mean change in FEV1 from baseline for Bronchitol was 126mL versus a control difference of 15.76mL over 26 weeks. The difference was statistically significant at the level of $p < 0.001$.

Abstract Number 368: *'Pilot study of inhaled dry powder mannitol (Bronchitol) in young people with CF hospitalised with pulmonary exacerbation'*

In this pilot clinical trial, the objective was to assess the safety and effect of Bronchitol when used for two weeks as an adjunct to intravenous antibiotics in young people admitted to hospital with a pulmonary exacerbation.

Pharmaxis CEO Dr Alan Robertson said, "Now that Bronchitol is commercially available in Europe and Australia it is important to use the extensive data from the clinical programmes to help guide clinicians on how best to introduce Bronchitol. These additional analyses presented at the North American CF conference provide further insights into the role of Bronchitol in cystic fibrosis patient care."

Bronchitol has Orphan Drug Designation in the U.S., Europe and Australia and is approved for marketing in Australia and throughout the European Union. An application has been submitted for marketing approval in the U.S.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson – Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

RELEASED THROUGH:**Australia:**

Felicity Moffatt, phone +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory disorders. Its product Aridol® for the assessment of asthma is sold in key international markets. Its product Bronchitol® for cystic fibrosis is recently launched in Europe and Australia and its development pipeline of products includes, Bronchitol for bronchiectasis, PXS64 for the treatment of lung fibrosis, ASM8 for asthma and PXS4728 for fibrotic disease. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office and manufacturing facilities are located in Sydney. For more information about Pharmaxis, go to www.pharmaxis.com.au or contact Investor Relations on phone +61 2 9454 7200.

About Bronchitol

Bronchitol has been developed to help clear mucus (a major source of lung infections), improve lung function and reduce exacerbations in patients with cystic fibrosis.

Bronchitol is a proprietary formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. Bronchitol hydrates the lungs, helps restore normal lung clearance, and allows patients to clear mucus more effectively. Clinical studies have shown Bronchitol to be effective and well tolerated in treating patients with cystic fibrosis.

About Cystic Fibrosis

In a healthy person, there is a constant flow of mucus over the surfaces of the air passages in the lungs, removing debris and bacteria. In CF, an inherited disease, a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely restricting the natural airway-clearing process. It also increases the potential for bacteria to become trapped and for inflammation, thus creating an unhealthy lung environment that leads to life-threatening lung infections.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval.
